Results In the preoperative setting, PET/CT provided additional diagnostic information in 42/149 (28%) patients. In particular, 17/70 (24%) patients at stage III were converted into stage IV and 4/68 (6%) at stage II were upstaged to IV. In the postoperative setting, PET/CT upstaged the disease in both stage IIIC and stage IV in 14/126 (11%) cases. At the end of follow-up, 28/271 (10%) patients died from BC and 40 (15%) had a recurrence of disease. On Kaplan-Meier analysis, patients with a positive PET/CT other than the primary tumor site showed both a worse overall survival and a worse disease-free survival compared with their counterpart (76 vs. 92%; P = 0.063 and 65 vs. 100%; P < 0.001). Conversely, in the postoperative setting, no differences in overall survival and disease-free survival were found between patients with positive and negative PET/CT findings (both P > 0.05). On multivariate Cox-regression analysis, a positive PET/CT was a significant predictive factor of a poor prognosis in the preoperative setting. The significance was lost in the postoperative setting.
Introduction
Breast cancer (BC) is a heterogeneous disease characterized by different biological pathways, expressions, and prognoses. Several factors have been linked to the poor prognosis, associated with breast cancer, including large tumor size, higher tumor grade, mitotic rate, lymphovascular space invasion, increased expression of HER2, and lower estrogen and progesterone receptor expression [1, 2] . In accordance with most common guidelines, patients with BC would be staged by clinical evaluation, mammography, axillary ultrasound (US), chest radiography, and liver-US, whereas in case of locally advanced disease (i.e. in case of large cancer and homolateral axillary lymph node invasion), computed tomography (CT) and bone scintigraphy (BS) are warranted. Furthermore, the latest European Society of Medical Oncology guidelines add that PET/CT with fluorine-18-fluorodeoxyglucose ( 18 F-FDG) would be advisable in case of high-risk BC, that is, in locally advanced or triple-negative or HER2 + or high-grade cancer [3] . PET/CT scanning can replace traditional imaging for staging in patients who are candidates for neoadjuvant chemotherapy as well as those with locally advanced and/or inflammatory disease because of their high risk of having metastatic disease [4] . Groheux et al. [5] have reported the advantages of using PET/CT for the initial staging of advanced BC compared with conventional imaging (such as CT and BS). However, no data on the diagnostic and prognostic role of 18 F-FDG PET/CT after surgery in patients with high-risk BC have been extensively defined. The primary end-point of the present study was to determine the value of 18 F-FDG PET/CT in patients with BC in the preoperative and the postoperative settings. The secondary aims were as follows: (i) to determine the impact of 18 F-FDG PET/CT on treatment planning and (ii) to assess the prognostic implications in terms of disease-free survival (DFS) and overall survival (OS) in both groups of patients (preoperative and postoperative).
Patients and methods

Patient selection
From November 2011 to January 2015, we prospectively collected data from 275 women (age: 53 12 years; range: 27-89 years) diagnosed with breast cancer who underwent an 18 F-FDG PET/CT examination before [149 (54.2%)] or after surgery [126 (45.8%)]. The inclusion criteria were as follows: (a) known history of BC; (b) advanced disease (positive axillary lymph nodes or large tumor mass at clinical evaluation) or HER2-positive or triple-negative or highgrade cancer. In the preoperative setting, patients who had already undergone neoadjuvant therapy before PET/CT examinations were excluded. In the postoperative setting, we selected patients who underwent PET/CT exams in the early phase before systemic therapy or local radiotherapy. The study was carried out in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants included in the study. In accordance with our Institutional policy, approval was obtained from our local Ethical Committee (notification number 23/2015).
Determination of initial stage and histopathological characteristics
Initial stage was determined according to the American Joint Committee of Cancer Staging Manual, such as stage I (composed of stage IA and IB), stage IIA, stage IIB, stage III (composed of stage IIIA, IIIB, and IIIC), and stage IV [6] . Initial clinical stage was determined from clinical examination, mammography, breast US, and, if available, breast MRI or surgical findings. In all cases, histotype, nuclear grade, estrogen receptor (ER), and progesterone receptor (PR) expression, proliferative activity (Ki-67), and HER2 status were required, and the patients were classified according to the St Gallen molecular subtypes [7] . Breast lesions were classified into five molecular subtypes according to the 12th International Breast Conference recommendations [8] . These subtypes were primarily derived from large-scale epidemiological data and are based on RNA expression profile. We therefore used a panel of immunohistochemical markers for ER, PR, HER2, and Ki-67 to categorize our patients into one of the five molecular subtypes: (i) luminal A: ERpositive and/or PR-positive, HER2-negative and Ki-67 low (< 14%); (ii) luminal B-HER2 (−): ER-positive and/or PR-positive, HER2-negative, and Ki-67 high (≥14%); (iii) luminal B-HER2 (+): ER-positive and/or PR-positive, HER2-positive and any Ki-67 index; (iv) HER2 (+): ERnegative, PR-negative, and HER2 positive; and (v) basal or triple negative: ER, PR, and HER2 negative. The Ki-67 index is used primarily to differentiate between luminal A and luminal B HER2 (−) subtypes.
Treatment approaches and verification of metastases
All patients with newly discovered distant metastases were verified by pathology. However, if histology was not available, follow-up imaging was used. For local extraaxillary nodal metastases, pathologic verification was preferred.
F-FDG PET/CT acquisition and interpretation
Whole-body 18 F-FDG PET/CT was performed using a dedicated PET/CT scanner (Biograph 16; Siemens Medical Solutions, Hoffman Estates, Illinois, USA) updated with high-definition software. Emission images ranging from the proximal femur and the base of the skull were acquired for 2-3 min (on the basis of the body weight) per acquisition field of view 60 min from the injection of 18 F-FDG (3 MBq/kg/body weight). Acquired images were reconstructed using the attenuation weighted-ordered subset expectation maximization iterative reconstruction with two iterations and eight subsets. Two experienced specialists (L.E. and G.S.) evaluated fused PET/CT images. On visual analysis, increased 18 F-FDG uptake on the basis of either highly suspicious or definite CT morphologic changes and not corresponding to physiological uptake patterns was recorded as positive. The confirmation of abnormal uptake was provided by semiquantitative data. The semiquantitative evaluation of 18 F-FDG uptake was performed using maximum standardized uptake value (SUV max ), obtained by generating a three-dimensional volume of interest based on region-growing procedures, using a cutoff of at least 2.5. In case of a low tumor-tobackground ratio, rendering an automated volume of interest generation unreliable, SUV was derived from a manually drawn three-dimensional volume of interest. Clinical staging by PET/CT was divided into five categories (stages I, II, IIIA/B, IIIC, and IV) in accordance with the site of 18 F-FDG uptake. In particular, stage IIIA/B and stage IIIC comprised all patients with a significant uptake in the lymph nodes of I-II levels and the homolateral internal mammary chain, and in the lymph nodes of III level, supraclavicular and internal mammary chain, respectively.
Follow-up
The follow-up data of enrolled patients were obtained by telephonic interviews and the revision of medical charts between 1 May and 1 June 2016 by a researcher blinded (A.R.C.) to image results. To determine follow-up time, the date of the last examination or consultation was used. Defined events included recurrence of disease and all causes of mortality. Death from any cause was later confirmed by the revision of a specific certificate.
Statistical analysis
The normality of the variables was verified using the Shapiro-Wilk test. Medians and ranges or mean and SD were used to summarize continuous variables and frequencies, and percentages were used to summarize categorical variables. Associations for paired samples were assessed using the Mann-Whitney or Student's t-test. Comparisons between dichotomized variables were performed using the χ 2 -test, or the Fischer's exact test, as appropriate. DFS and the OS were defined as the length of time from the date of PET/CT to any relapse (local or distance recurrence or contralateral breast cancer, or second cancer) and to death from any cause, respectively. Survival curves were generated using the Kaplan-Meier method and compared using the log rank test. Univariate and multivariate analysis was based on a Cox-regression model to compare the predictive power of 18 F-FDG PET/ CT with that of other outcome predictors, such as age, clinical stage, grade, expression of estrogen, progesterone and HER2 receptors, and proliferation index. P less than 0.05 was considered statistically significant. Statistical analysis was carried out using SPSS software (version 20; SPSS Inc., Chicago, Illinois, USA).
Results
Preoperative setting
The characteristics of the preoperative group of patients are reported in Table 1 . The majority of patients had a stage IIB-III. More often, an invasive ductal, luminal B, and triple-negative cancer were reported. None of the patients was symptomatic for metastatic disease. 18 F-FDG PET/CT was positive in all 149 patients, in particular, 146 (98%) at breast level, 107 at axillary level, and 40 at distant lymph nodes. A significant 18 F-FDG uptake was found in 14 (9.4%) patients at the bone level, in six (4%) patients in the liver, and in five (3.4%) in the lung. On the basis of PET/CT imaging, 45 patients were upstaged into stage IIIC and stage IV (Fig. 1a) . However, PET/CT was falsely positive in three patients with suspicion of bone metastases. Therefore, the findings of PET/CT provided additional diagnostic information in 42/149 (28%) patients.
In particular, 17/70 patients at stage III were converted into stage IV after the introduction of PET/CT in the diagnostic flow-chart. Similarly, 4/68 patients at stage II were upstaged to IV. Interestingly, out of eight patients with a stage I cancer, one with a triple-negative cancer was upstaged to stage IV, for the presence of a single skeletal lesion, later confirmed at histological assessment. From a clinical point of view, change in treatment was reported in 15 patients after the inclusion of PET/CT with 18 F-FDG. In particular, one patient received an enlarged surgical approach, 12 patients had systemic treatment, and two received a combination of systemic and local treatment (i.e. external beam radiotherapy). F-FDG PET/CT was positive in 50 (39.7%) postoperative patients. Seven (5.6%) patients showed a positive PET/CT at the breast level, 13 (10.3%) in homolateral axillary lymph nodes, 16 (12.7%) in extraaxillary lymph nodes, and eight (6.4%) in distant organs (five and three, respectively, in the bone and in the lung). PET/CT results were falsely positive in 24 out of 50 (48%) patients: 18 in the surgical bed, two in the internal mammary chain, one in the spleen, one in the adrenal gland, one in the bone, and one in the lung. The uptake in the spleen was because of an old spleen infarction. The uptake in the adrenal gland was because of an adrenal adenoma. The uptake in the bone was associated with a recent trauma and the uptake in the lung was because of lung sarcoidosis.
Nevertheless, the inclusion of PET/CT in the diagnostic algorithm of this setting of patients upstaged the disease to stage IIIC and stage IV in 14 (11%) cases (Fig. 1b) . The highest disagreement between pathological staging and PET/CT staging was reported in stage III (16%). Changes in treatment strategies, after the inclusion of PET/CT, were found in 14.3% of patients. In particular, three patients underwent further surgery, eight received additional external beam radiotherapy, and the remaining received a more aggressive systemic treatment or a combination of local and systemic therapies.
Conventional imaging
CT, BS, and MRI were available in 69 patients, respectively, in 33 and 36 for the preoperative and the postoperative setting. The agreement between conventional imaging and PET/CT findings was low in the postoperative setting (k = 0.357; P = 0.018). In this setting, bone metastases and lung nodules were missed by BS and chest-CT, respectively. In contrast, the findings from conventional imaging and PET/CT in the preoperative setting agreed in 88% of cases.
Prognostic impact
After a median period of 44 months (2-57 months), 28 out of 271 (10%) patients died from breast cancer and 40 (15%) had a recurrence of disease. In total, 46 (17%) events occurred in 271 patients. Four patients were lost to follow-up. The number of events was significantly higher in the preoperative setting compared with the postoperative setting (31/146 had events in the preoperative setting and 15/125 in the postoperative setting; 21 vs. 12%; P < 0.05; Table 2 ). However, the mortality rate for BC was similar between the two groups (11 vs. 10%, respectively, for the preoperative and the postoperative setting; P = 0.714). On Kaplan-Meier analysis, patients with a positive PET/CT finding other than the primary tumor site showed both a worse OS and DFS compared with their counterparts (76 vs. 92%; P = 0.063 and 65 vs. 100%; P < 0.001). Conversely, in the postoperative setting, no differences were found between patients with positive and negative PET/CT findings (both P > 0.05). Figures 2 and 3 report the survival curves for the preoperative and postoperative setting.
Additional Kaplan-Meier analyses were carried out to test the prognosis in accordance with clinical/pathological stage and PET stage (Fig. 4) . As shown, in the preoperative setting, PET stage could better stratify the risk of disease recurrence and overall survival, especially in patients with stage I-II and those with stage III-IV. Moreover, in the postoperative setting, stage PET could stratify the risk of disease recurrence in stage III-IV patients. On univariate and multivariate Cox-regression analyses, a positive PET/CT in the axillary lymph nodes was a significant predictive factor of a poor prognosis (hazard ratio: 5.96; 95% confidence interval: 1.373-25.87; P = 0.017; Table 3 ) in the preoperative setting. The significance was lost in the postoperative setting, although on univariate analysis, a positive 18 F-FDG PET/CT at the bone level was predictive of a unfavorable DFS (hazard ratio: 11.9; 95% confidence interval: 2.978-48.34; P = 0.001; Table 3 ).
Discussion
The role of 18 F-FDG PET/CT in patients with breast cancer is an important and large field of research. Overall and recurrence-free survival curves in accordance with PET/CT findings outside the primary cancer in the preoperative setting. CT, computed tomography.
Different studies have considered the advantages to include 18 F-FDG PET/CT in the initial diagnostic algorithm of BC, but with different and heterogeneous effects on the modification of the clinical stage, treatment strategies, and prognosis. Table 3 reports a collection of data from the available literature focusing on the impact of 18 F-FDG PET/CT in the preoperative and postoperative setting.
In the present study, in the preoperative setting, PET/ CT could modify the clinical staging in 28% of cases. In particular, in patients with advanced disease (stage II-III), it can provide the identification of distant metastases, as also reported by other authors, although with a variable range (10-71%; Table 4 ). Similarly, in the postoperative setting, both stage II and stage III seem to have some advantages from 18 F-FDG PET/CT. In particular, 6/56 patients with stage III disease showed a significant uptake of 18 F-FDG in the lymph nodes of the third level in the supraclavicular and in the internal mammary chain. Moreover, 11 out of 126 patients had distant metastases after primary treatment. These results are very important because the treatment of patients would be changed or modify if PET/CT is performed preoperatively. Although the detection of unsuspected local extra-axillary nodal disease does not have the same impact on patient care as the detection of distant metastases, detection of such nodal disease may still increase the patient's stage, affect prognosis, and lead to changes in a patient's treatment plan, such as additional surgery or radiotherapy. Several studies have shown the value of 18 F-FDG PET/CT over other imaging modalities for the detection of local extra-axillary nodal disease [13, 14, 19] . However, in the present study, we found that the addition of 18 F-FDG PET/CT has a significant advantage in the clinical staging for preoperative and postoperative setting because 24 and 16% of stage III patients showed distant metastases. As is known, in the era of multimodality imaging and therapy, patients with stage IV disease can be treated in a curable way [20] . Particular attention should be paid to the false-positive results in the postoperative setting. We found that 24 out of 126 patients (false-positive rate = 19%) had a falsepositive 18 F-FDG uptake in different organs. The most common false finding was reported in the surgical bed [18 (75%)], compatible with the presence of inflammatory cells after breast removal.
Most of the patients in the preoperative setting showed a positive 18 F-FDG uptake in the axillary and distant lymph nodes. Overall, 9.4% showed a significant uptake in the bone and a few cases in the liver and lung. The findings were false positives in a few cases [6/172 (3.5%) ]. In the postoperative setting, the most common site of a significant 18 F-FDG uptake at PET/CT was distant lymph nodes, followed by the axillar lymph nodes, bone, and lung. The number of false-positive findings in this setting was 10/37 (27%). Therefore, on the basis of this information, the number of false-positive findings was significantly higher in patients undergoing 18 F-FDG PET/CT and prognosis in high risk breast cancer Evangelista et al. 543
PET/CT after surgery. This finding considerably affects the final results of the current study.
The subsequent impact on treatment planning was, however, higher in the postoperative setting than the preoperative setting (14.3 vs. 10%). Although we expected that in the preoperative setting many patients would switch to a nonsurgical path after the inclusion of 18 F-FDG PET/CT, a higher rate of management changes was found in the postoperative setting. Indeed, more treatment options are available in the postoperative setting where patients can be treated with: (i) adjuvant chemotherapy; (ii) adjuvant hormonal therapy; (iii) adjuvant radiation therapy; and (iv) the combination of more than of the treatments. Also, from the review of literature data (Table 4) , we found that the change in treatment in the preoperative setting showed a minimum value of 8% and a maximum of 28%, whereas in the postoperative phase, it was 37%. However, in the postoperative setting, PET stage could better stratify the risk of disease recurrence than pathological stage. Nevertheless, it is interesting to note that in this latter setting of patients, the prognosis was similar for patients with a positive and negative 18 F-FDG PET/CT, although the trend was unfavorable in patients with a positive scan. Conversely, in the preoperative setting, patients with a positive PET/CT outside the primary cancer had a worse prognosis than those with a negative scan. A recent paper by García Vicente et al. [16] reported that the preoperatively SUV max in the primary tumor and in the axillary lymph nodes are predictive factors of DFS and OS. However, this is the first study that has considered the prognostic impact of 18 F-FDG PET/CT in the postoperative setting of patients with high-risk BC.
The rationale of accepting a new technology must be centered around the system having prognostic accuracy and also providing improved treatment outcome in a costeffective manner. Recent data from Miquel-Cases et al. [21] reported that 18 F-FDG PET/CT for the screening of distant metastases in patients with stage II/III breast cancer is cost-effective in USA and in the Netherlands. The authors found that 18 F-FDG PET/CT is expected to result in incremental quality-adjusted life year gains in all BC subtypes. Nevertheless, no studies are now available on the gain in cost-effectiveness in the postoperative setting. 18 F-FDG PET/CT examination and, therefore, we could not provide any conclusion on the role of conventional imaging against 18 F-FDG PET/CT in the preoperative and postoperative setting. Nevertheless, in 36 patients, we found a high disagreement in the postoperative setting (agreement only in 36% of patients).
Conclusion
In the preoperative setting, PET/CT can provide additional diagnostic and prognostic information. Therefore, patients with stage II-III would benefit from 18 F-FDG PET/CT. Conversely, in the postoperative setting, PET/ CT adds diagnostic information and therefore it can change treatment strategies. However, its prognostic assessment is scarce, although patients with a positive scan have a worse trend in DFS than those with a negative PET/CT. We encourage the design of a multicenter trial that can provide definitive information on the role of 18 F-FDG PET/CT in patients with high-risk BC after surgical treatment and to guide a sophisticated cost-effective analysis.
